The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Azacitidine and venetoclax +/- gemtuzumab ozogamicin in pediatric patients with R/R acute leukemias
Sarah Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, discusses a retrospective cohort analysis evaluating the combination of azacitidine and venetoclax +/- gemtuzumab ozogamicin for the treatment of pediatric patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Dr Tasian highlights the complete remission (CR) rates observed in patients and further comments on the promise of this combination regimen. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Aleta Biotherapeutics: Consultancy; Beam Therapeutics: Research Funding; bluebird bio: Consultancy; Syndax Pharmaceuticals: Consultancy; Kura Oncology: Consultancy, Research Funding; GSK: Consultancy; Incyte Corporation: Research Funding.
